Targeting B Cells for Inflammatory Bowel Disease Treatment: Back to the Future

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2020 Nov 9

PMID 33166872

Citations 28

Authors

Tomas Castro-Dopico

Jean-Frederic Colombel

Saurabh Mehandru

Affiliations

Soon will be listed here.

Abstract

B cells are critical to immune homeostasis at mucosal surfaces including those of the gastrointestinal tract. B cell-related abnormalities, comprising of a lympho-plasmacytic infiltrate, as well as anti-microbial antibodies, are well reported in patients with inflammatory bowel disease (IBD). However, B cell-targeting is not part of the therapeutic armamentarium in IBD. Recently, driven by the identification of genetic associations between IgG Fc receptors and IBD susceptibility, there has been renewed interest in defining the immunobiology of B cells during mucosal inflammation. Functional studies have demonstrated mechanisms of IgG-mediated disease pathogenesis and deep mucosal immunophenotyping using single cell RNA sequencing has elaborated a significant remodelling of the B cell compartment in IBD. In light of these novel data, here we discuss potential strategies to target B cell immunity in IBD. Finally, we discuss potential risks and pitfalls of these approaches and emphasize on distinguishing between homeostatic and pathological B cell signatures, allowing for a data-based, prudent therapeutic approach.

Citing Articles

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis.

Chen H Front Pharmacol. 2025; 15:1521726.

PMID: 39917326 PMC: 11799251. DOI: 10.3389/fphar.2024.1521726.

Identifying Common Genetic Etiologies Between Inflammatory Bowel Disease and Related Immune-Mediated Diseases.

Liu X, Li D, Zhang Y, Liu H, Chen P, Zhao Y Biomedicines. 2024; 12(11).

PMID: 39595128 PMC: 11592296. DOI: 10.3390/biomedicines12112562.

B cell academy of the gut: an update on gut associated germinal centre B cell dynamics.

Wichmann C, Wirthgen E, Nowosad C, Dabritz J Mol Cell Pediatr. 2024; 11(1):7.

PMID: 39147924 PMC: 11327226. DOI: 10.1186/s40348-024-00180-y.

Automated spatial omics landscape analysis approach reveals novel tissue architectures in ulcerative colitis.

Holman D, Rubin S, Ferenc M, Holman E, Koron A, Daniel R Sci Rep. 2024; 14(1):18934.

PMID: 39147769 PMC: 11327370. DOI: 10.1038/s41598-024-68397-5.

Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.

Mestrovic A, Perkovic N, Bozic D, Kumric M, Vilovic M, Bozic J Biomedicines. 2024; 12(7).

PMID: 39062093 PMC: 11274502. DOI: 10.3390/biomedicines12071520.

References

Alexander T, Sarfert R, Klotsche J, Kuhl A, Rubbert-Roth A, Lorenz H . The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015; 74(7):1474-8. PMC: 4484251. DOI: 10.1136/annrheumdis-2014-206016. View

Bunker J, Flynn T, Koval J, Shaw D, Meisel M, McDonald B . Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity. 2015; 43(3):541-53. PMC: 4575282. DOI: 10.1016/j.immuni.2015.08.007. View

Gomez de Aguero M, Ganal-Vonarburg S, Fuhrer T, Rupp S, Uchimura Y, Li H . The maternal microbiota drives early postnatal innate immune development. Science. 2016; 351(6279):1296-302. DOI: 10.1126/science.aad2571. View

Clegg C, Rulffes J, Haugen H, Hoggatt I, Aruffo A, Durham S . Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int Immunol. 1997; 9(8):1111-22. DOI: 10.1093/intimm/9.8.1111. View

Uzzan M, Ko H, Rosenstein A, Pourmand K, Colombel J, Mehandru S . Efficient long-term depletion of CD20 B cells by rituximab does not affect gut-resident plasma cells. Ann N Y Acad Sci. 2018; 1415(1):5-10. PMC: 6368409. DOI: 10.1111/nyas.13577. View

Pyzik M, Sand K, Hubbard J, Andersen J, Sandlie I, Blumberg R . The Neonatal Fc Receptor (FcRn): A Misnomer?. Front Immunol. 2019; 10:1540. PMC: 6636548. DOI: 10.3389/fimmu.2019.01540. View

Stuber E, Strober W, Neurath M . Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996; 183(2):693-8. PMC: 2192468. DOI: 10.1084/jem.183.2.693. View

Castro-Dopico T, Clatworthy M . Mucosal IgG in inflammatory bowel disease - a question of (sub)class?. Gut Microbes. 2019; 12(1):1-9. PMC: 7524157. DOI: 10.1080/19490976.2019.1651596. View

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

10.

Theodoratou E, Campbell H, Ventham N, Kolarich D, Pucic-Bakovic M, Zoldos V . The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol. 2014; 11(10):588-600. DOI: 10.1038/nrgastro.2014.78. View

11.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

12.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

13.

Kett K, Rognum T, Brandtzaeg P . Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology. 1987; 93(5):919-24. DOI: 10.1016/0016-5085(87)90552-x. View

14.

Thai L, Le Gallou S, Robbins A, Crickx E, Fadeev T, Zhou Z . BAFF and CD4 T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context. Blood. 2018; 131(14):1545-1555. DOI: 10.1182/blood-2017-06-789578. View

15.

Lauc G, Huffman J, Pucic M, Zgaga L, Adamczyk B, Muzinic A . Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013; 9(1):e1003225. PMC: 3561084. DOI: 10.1371/journal.pgen.1003225. View

16.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

17.

Choung R, Princen F, Stockfisch T, Torres J, Maue A, Porter C . Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016; 43(12):1300-10. DOI: 10.1111/apt.13641. View

18.

van Montfoort N, t Hoen P, Mangsbo S, Camps M, Boross P, Melief C . Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells. J Immunol. 2012; 189(1):92-101. DOI: 10.4049/jimmunol.1103703. View

19.

Uhlig H, McKenzie B, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R . Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006; 25(2):309-18. DOI: 10.1016/j.immuni.2006.05.017. View

20.

Pereira M, Duraes C, Catarino T, Costa J, Cleynen I, Novokmet M . Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis. Clin Transl Gastroenterol. 2020; 11(4):e00166. PMC: 7263653. DOI: 10.14309/ctg.0000000000000166. View